• Latest Posts

AI program finds multiple influenza drug targets

Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform

AI program yields multiple novel RSV drug targets

Poolbeg expands POLB 001 into oncology

Poolbeg identifies new potential drug candidates for RSV infections 

Poolbeg influenza trial successfully completed


Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments